X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims for the development of long-acting implants that deliver antisense oligonucleotides using Celanese VitalDose® drug delivery platform and Secarna’s proprietary ASO drug discovery and development platform.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Celanese
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 20, 2024
Details:
Under the collaboration, the companies will work together to generate novel Antisense Oligonucleotide therapies directed at targets that play a critical role in diseases of the Central Nervous System.
Lead Product(s): Antisense Oligonucleotide
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: SciNeuro Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 27, 2023
Details:
Secarna will employ its commercially validated discovery and development platform, LNAplus™, to generate ASO candidates against selected targets that potentially play a central role in the ex vivo optimization of personalized T cell therapies being developed by Achilles.
Lead Product(s): Antisense Oligonucleotide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Achilles Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 10, 2021
Details:
As part of the collaboration, Secarna will employ its commercially validated discovery and development platform, LNAplus™ to generate antisense oligonucleotide candidates against targets relevant for the treatment of neurodegenerative diseases.
Lead Product(s): Antisense Oligonucleotides
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Denali Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 26, 2021
Details:
Partnership creates an opportunity for biotech and pharmaceutical companies to enter the growing field of antisense therapeutics by partnering with Evotec and Secarna and to gain access to the companies' co-owned pipeline through a variety of individual deal structures.
Lead Product(s): Antisense oligonucleotide therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Evotec
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 05, 2020
Details:
Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.
Lead Product(s): Antisense Oligonucleotides
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sun Yat-sen University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2020
Details:
Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.
Lead Product(s): Antisense oligonucleotide therapies
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lipigon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
